evidencegaps
Findings

What do systematic reviews say?

Refine by population, intervention, comparison or outcome
More filters
Evidence found and GRADE certainty

1,257 questions · 1,337 findings · 183 reviews

Sort:Best matchNewestHighest certaintyDownload CSV
No studies found 175 · 13.1%GRADE not reported 212 · 15.9%Very low 286 · 21.4%Low 341 · 25.5%Moderate 254 · 19%High 69 · 5.2%

Alemtuzumab 12 mg vs interferon beta‐1a

Number of participants with new or enlarging T2‐hyperintense lesions on MRI · adults with relapsing–remitting multiple sclerosis

The review found no eligible studies for this question.

1 finding from 1 review

Alemtuzumab 12 mg vs interferon beta‐1a

Dropout · adults with relapsing–remitting multiple sclerosis

It is very uncertain whether alemtuzumab 12 mg changes dropouts Assessed by: number of participants who dropped out compared with interferon beta‐1a (very low certainty).

1 finding from 1 review

Alemtuzumab 24 mg vs interferon beta‐1a

Proportion of participants with relapse‐free survival at ≥ 12 months · adults with multiple sclerosis Interventions: immunosuppressive and immunomodulatory drugs Comparator: placebo Outcome: withdrawals due to…

Alemtuzumab 24 mg may leads to lower relapse‐free survival compared with interferon beta‐1a (low certainty).

1 finding from 1 review

Alemtuzumab 24 mg vs interferon beta‐1a

Sustained disease progression‐free survival · adults with multiple sclerosis Interventions: immunosuppressive and immunomodulatory drugs Comparator: placebo Outcome: withdrawals due to…

Alemtuzumab 24 mg may leads to lower sustained disease progression‐free survival compared with interferon beta‐1a (low certainty).

1 finding from 1 review

Alemtuzumab 24 mg vs interferon beta‐1a

Adverse events, including serious adverse events Assessed by: number of participants with ≥ 1 event · adults with multiple sclerosis Interventions: immunosuppressive and immunomodulatory drugs Comparator: placebo Outcome: withdrawals due to…

Alemtuzumab 24 mg showed no clear difference in adverse events, including serious adverse events Assessed by: number… compared with interferon beta‐1a (low certainty).

1 finding from 1 review

Summary of findings 2: Immunotherapies vs placebo

(1512) · adults with multiple sclerosis Interventions: immunosuppressive and immunomodulatory drugs Comparator: placebo Outcome: withdrawals due to…
2 findings from 1 review

Summary of findings 2: Immunotherapies vs placebo

(3774) · adults with multiple sclerosis Interventions: immunosuppressive and immunomodulatory drugs Comparator: placebo Outcome: withdrawals due to…
2 findings from 1 review

Summary of findings 2: Immunotherapies vs placebo

(3044) · adults with multiple sclerosis Interventions: immunosuppressive and immunomodulatory drugs Comparator: placebo Outcome: withdrawals due to…
2 findings from 1 review

Summary of findings 2: Immunotherapies vs placebo

(1935) · adults with multiple sclerosis Interventions: immunosuppressive and immunomodulatory drugs Comparator: placebo Outcome: withdrawals due to…
2 findings from 1 review

Summary of findings 2: Immunotherapies vs placebo

(543) · adults with multiple sclerosis Interventions: immunosuppressive and immunomodulatory drugs Comparator: placebo Outcome: withdrawals due to…
2 findings from 1 review

Summary of findings 2: Immunotherapies vs placebo

(4360) · adults with multiple sclerosis Interventions: immunosuppressive and immunomodulatory drugs Comparator: placebo Outcome: withdrawals due to…
2 findings from 1 review

Summary of findings 2: Immunotherapies vs placebo

(1941) · adults with multiple sclerosis Interventions: immunosuppressive and immunomodulatory drugs Comparator: placebo Outcome: withdrawals due to…
2 findings from 1 review

Summary of findings 2: Immunotherapies vs placebo

(295) · adults with multiple sclerosis Interventions: immunosuppressive and immunomodulatory drugs Comparator: placebo Outcome: withdrawals due to…
2 findings from 1 review

Summary of findings 2: Immunotherapies vs placebo

(0) · adults with multiple sclerosis Interventions: immunosuppressive and immunomodulatory drugs Comparator: placebo Outcome: withdrawals due to…
2 findings from 1 review

Summary of findings 2: Immunotherapies vs placebo

(2134) · adults with multiple sclerosis Interventions: immunosuppressive and immunomodulatory drugs Comparator: placebo Outcome: withdrawals due to…
2 findings from 1 review

Summary of findings 2: Immunotherapies vs placebo

(889) · adults with multiple sclerosis Interventions: immunosuppressive and immunomodulatory drugs Comparator: placebo Outcome: withdrawals due to…
2 findings from 1 review